3cf35e3b-812f-4cc1-bd37-e78fd6af6dc4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- ANGIOGENESIS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- GLYCOLYSIS+0.300
- MTORC1_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.300
- ANDROGEN_RESPONSE+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- UV_RESPONSE_DN+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.300
- MYC_TARGETS_V2-0.300
- HEDGEHOG_SIGNALING-0.200
- HEME_METABOLISM-0.200
- IL2_STAT5_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- P53_PATHWAY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 48155bad-7de9-401d-a495-972cbbb8f276 | — | — | 0.695 |
| 2 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.694 |
| 3 | R146 | — | — | 0.659 |
| 4 | SRR493955 | — | cohortSC | 0.650 |
| 5 | R325 | — | — | 0.646 |
| 6 | TCGA-C8-A12Z-01A-11R-A115-07 | — | C | 0.643 |
| 7 | MNG601 | — | — | 0.641 |
| 8 | acff2b90.e0b8.4523.8db6.6cce367439be | — | cohortA3 | 0.640 |
| 9 | TCGA-D8-A1X7-01A-11R-A14M-07 | — | B | 0.637 |
| 10 | TCGA-66-2789-01A-01R-0980-07 | — | cohortSQ1 | 0.633 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |